Cargando…
Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy
PURPOSE: To evaluate the diagnostic accuracy of SelectMDx and its association with multiparametric magnetic resonance (mpMRI) in predicting prostate cancer (PCa) and clinically significant PCa (csPCa) on prostate biopsies among men scheduled for initial prostate biopsy. METHODS: In this single-cente...
Autores principales: | Busetto, Gian Maria, Del Giudice, Francesco, Maggi, Martina, De Marco, Ferdinando, Porreca, Angelo, Sperduti, Isabella, Magliocca, Fabio Massimo, Salciccia, Stefano, Chung, Benjamin I., De Berardinis, Ettore, Sciarra, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217060/ https://www.ncbi.nlm.nih.gov/pubmed/32681273 http://dx.doi.org/10.1007/s00345-020-03359-w |
Ejemplares similares
-
SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study
por: Maggi, Martina, et al.
Publicado: (2021) -
Adding systematic biopsy to magnetic resonance ultrasound fusion targeted biopsy of the prostate in men with previous negative biopsy or enrolled in active surveillance programs: A prospective single center, randomized study
por: Porreca, Angelo, et al.
Publicado: (2020) -
Comparison of the clinical usefulness of different urinary tests for the initial detection of bladder cancer: a systematic review
por: Sciarra, Alessandro, et al.
Publicado: (2021) -
A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Novel Hormonal Therapies for Non-Metastatic Castration-Resistant Prostate Cancer: An Update From Mature Overall Survival Data
por: Maggi, Martina, et al.
Publicado: (2021) -
Cribriform pattern does not have a significant impact in Gleason Score ≥7/ISUP Grade ≥2 prostate cancers submitted to radical prostatectomy
por: Flammia, Simone, et al.
Publicado: (2020)